Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed adenocarcinoma of
             esophagus,gastroesophageal junction, or stomach which is Gli-1 positive (labeling
             index [LI] greater than or equal to 5%). Testing is to be performed in a CLIA
             certified laboratory. The patients must have an archival tumor sample to facilitate
             this testing.

          2. Patients must have an unresectable locally advanced or metastatic adenocarcinoma.

          3. Patients agreeing to the optional biomarker study in the expansion phase only need to
             have an accessible primary tumor. (Optional biomarker studies will be done in up to 18
             patients in the expansion phase only.)

          4. Patient must have received at least one, and no more than two prior systemic therapies
             for metastatic cancer.

          5. Patients whose esophageal or GEJ cancer has become metastatic or unresectable locally
             advanced within 6 months of completing definitive therapy for localized or locally
             advanced cancer can be considered as having received one line of therapy for advanced
             cancer.

          6. Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as greater than 20 mm with
             conventional techniques or as greater than 10 mm with spiral CT scan.

          7. Male or female patients greater than or equal to 18 years old.

          8. ECOG performance status less than 2.

          9. Patients must have normal organ and marrow function as defined below: leukocytes
             greater than 3,000/mcL; absolute neutrophil count greater than1,500/mcL; platelets
             greater than 100,000/mcL; Hemoglobin (Hgb) greater than or equal to 9 g/dL
             (transfusions are allowed); total bilirubin within normal institutional limits;
             AST(SGOT)/ALT(SGPT) less than 2.5 x institutional upper limit of normal (ULN) or less
             than or equal to 5 x institutional ULN if liver metastasis are present; Serum
             creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or equal
             to 50ml/min; Plasma creatine phosphokinase (CK) less than 1.5 x ULN; INR less than or
             equal to 2; Fasting serum cholesterol less than or equal to 300 mg/dL OR less than or
             equal to 7.75 mmol/L AND fasting triglycerides less than or equal to 2.5 x ULN.

         10. Patient should be able to swallow and retain oral medications.

         11. Women of childbearing potential and men must use two forms of contraception
             (non-hormonal or barrier method of birth control; abstinence) prior to study entry and
             for the duration of study participation and for 6 months after the final dose of study
             treatment.

         12. Ability to understand and the willingness to sign a written informed consent document.
             Signed informed consent will be obtained prior to any screening procedures.

        Exclusion Criteria:

          1. Patients currently receiving anticancer therapies or who have received anticancer
             therapies within 4 weeks of the start of Everolimus and LDE225 (including
             chemotherapy, radiation therapy, antibody based therapy, etc.).

          2. Uncontrolled diabetes mellitus as defined by HbA1c greater than 8% despite adequate
             therapy. Patients with a known history of impaired fasting glucose or diabetes
             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must
             be monitored closely throughout the trial and adjusted as necessary.

          3. Patients who have any severe and/or uncontrolled medical conditions such as: a)
             unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction
             less than or equal to 6 months prior to start of Everolimus, serious uncontrolled
             cardiac arrhythmia, or any other clinically significant cardiac disease; b)
             symptomatic congestive heart failure of New York Heart Association Class III or IV; c)
             active (acute or chronic) or uncontrolled severe infection, liver disease such as
             cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable
             HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA); d) known severely impaired lung
             function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at
             rest on room air); e) active, bleeding diathesis.

          4. Patients who have a history of another primary malignancy, with the exceptions of:
             non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from
             which the patient has been disease free for greater than or equal to 3 years.

          5. Patients with a history of non-compliance to medical regimens or who are considered
             potentially unreliable or will not be able to complete the entire study.

          6. Pregnant or nursing (lactating) women.

          7. Women of child-bearing potential (WOCBP), defined as all women physiologically capable
             of becoming pregnant, must use highly effective methods of contraception during the
             study and 6 months after. Hormonal contraception methods (e.g. oral, injected,
             implanted) are not allowed as it cannot be ruled out that the study drug decreases the
             effectiveness of hormonal contraception. Highly effective contraception methods
             include combination of any two of the following: a) Placement of a non-hormonal
             intrauterine device (IUD) or non-hormonal intrauterine system (IUS); b) Barrier
             methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)
             with spermicidal foam/gel/film/cream/ vaginal suppository; c. Total abstinence (When
             this is in line with the preferred and usual lifestyle of the patient. Periodic
             abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and
             withdrawal are not acceptable methods of contraception.);

          8. (Continued from # 7): or d) Male/female sterilization. (Sterilization: Patient has had
             surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at
             least six weeks before taking study treatment. In case of oophorectomy alone, only
             when the reproductive status of the woman has been confirmed by follow up hormone
             level assessment. Male partner sterilization (with the appropriate post-vasectomy
             documentation of the absence of sperm in the ejaculate). [For female study patients,
             the vasectomized male partner should be the sole partner for that patient.]).

          9. (Continued from # 8): Women are considered post-menopausal and not of child-bearing
             potential if they have had 12 months of natural (spontaneous) amenorrhea with an
             appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or
             have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal
             ligation at least six weeks prior to randomization. In the case of oophorectomy alone,
             only when the reproductive status of the woman has been confirmed by follow up hormone
             level assessment is she considered not of child-bearing potential.

         10. Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate
             contraception, during the study and for 6 months after the end of treatment (Male
             patients must use highly effective (double barrier) methods of contraception (e.g.,
             spermicidal gel plus condom) for the entire duration of the study, and continuing
             using contraception and refrain from fathering a child for 6 months following the
             study drug. A condom is required to be used also by vasectomized men as well as during
             intercourse with a male partner in order to prevent delivery of the study treatment
             via seminal fluid.).

         11. Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

         12. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to LDE 225 or Everolimus in the study or other rapamycin analogs (e.g.
             sirolimus, temsirolimus).

         13. Patients who are receiving treatment with medications known to be moderate and strong
             inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have
             narrow therapeutic index, and that cannot be discontinued before starting treatment
             with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued at
             least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting
             treatment with LDE225.

         14. Patients receiving any medications or substances that are inhibitors or inducers of
             CYP 450 3A4 are ineligible.

         15. Patients who have neuromuscular disorders (e.g. inflammatory myopathies, muscular
             dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on
             concomitant treatment with drugs that are recognized to cause rhabdomyolysis, such as
             HMG CoA inhibitors (statins), clofibrate and gemfibrozil, and that cannot be
             discontinued at least 2 weeks prior to starting LDE225 treatment. Patients who are
             planning on embarking on a new strenuous exercise regimen after initiation of study
             treatment, should also be excluded. Muscular activities, such as strenuous exercise,
             that can result in significant increases in plasma CK levels should be avoided whilst
             on LDE225 treatment.

         16. Concurrent medical condition requiring the use of immunosuppressive medications or
             immunosuppressive doses of systemic or absorbable topical corticosteroids (doses
             greater than 10mg/day prednisone or equivalent). Inhaled or intranasal corticosteroids
             (with minimal systemic absorption) may be continued. Non-absorbed intra-articular
             steroid injections are allowed. The exception to the use of steroids is the treatment
             of serious adverse events (SAEs) such as pneumonitis and the prevention of emesis.

         17. Known history of HIV seropositivity.

         18. Patients who have received live attenuated vaccines within 1 week of start of
             Everolimus and during the study.

         19. Impaired cardiac function or clinically significant heart disease, including any one
             of the following: a) Angina pectoris within 3 months; b) Acute myocardial infarction
             within 3 months; c) QTcF greater than 450 msec for males and greater than 470 msec for
             females on the screening electrocardiogram (ECG); d) A past medical history of
             clinically significant ECG abnormalities or a family history of prolonged QT-interval
             syndrome; e) Other clinically significant heart disease (e.g. congestive heart
             failure, uncontrolled hypertension, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen).

         20. All patients known to be positive for hepatitis B will be excluded from the study, and
             those at high risk for hepatitis B infection will be screened.